Novartis and Malaria No More Campaign Provide Antimalarial Treatments in Zambia
Novartis delivers 2 million treatments of its pediatric antimalarial to Zambia in collaboration with Malaria No More's Power of One campaign.
Novartis reported that 2 million treatments of its pediatric antimalarial are arriving in Zambia due to collaboration with Malaria No More's Power of One campaign, a global digital fundraising operation. Zambia is the first beneficiary country of this campaign sponsored by Novartis. One million treatments of coartem dispersible have been funded through public donations and Novartis matched these with a further one million treatments.
The campaign, which launched to the public in September 2013, uses social, mobile, and e-commerce technologies, enabling the public to purchase treatments for children in Zambia. Novartis is supporting the campaign financially and has pledged to match up to one million treatments funded by the public every year through 2015. Since 2009, Novartis has delivered over 600 million treatments, of which more than 200 million were treatments developed specifically for children, without profit to malaria-endemic countries.
Source: Novartis
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
